Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK

Research output: Contribution to journalArticle

Abstract

Patient organisations contribute to many areas of pharmaceutical policy. In developing their organisational capacity, many turn to financial support from pharmaceutical companies, which may create conflicts of interests. However, the transparency of the industry's self-regulatory approach to the disclosure of payments to patient organisations has evaded scrutiny. Using company reports disclosing payments to UK patient organisations in 2012–2016, we evaluate the transparency of reporting using indicators derived from industry's European patient organisation Code. We found a large proportion of companies did not have any disclosure reports available despite many having made payments, confirmed by comparing with annual financial accounts of patient organisations registered as charities. Where disclosure reports were available, many payments were not adequately described, resulting in large portions of money being disclosed without clarity as to the payment type and purpose. We found companies were clearer regarding whether payments were financial or benefits-in-kind, but transparency was particularly inadequate as to whether it could be determined if payments were indirect or direct and restricted or unrestricted, and almost no companies mentioned the VAT status of payments. Our findings suggest that the industry's self-regulatory approach to transparency has not been working efficiently. We suggest ways for standardising and increasing the precision of information by pharmaceutical companies and advocate for the introduction of a centralised, and easily accessible national-level payment database.

Original languageEnglish
Pages (from-to)1244-1250
Number of pages7
JournalHealth Policy
Volume123
Issue number12
Early online date19 Aug 2019
DOIs
Publication statusPublished - 1 Dec 2019

Keywords

  • Disclosure
  • Patient organisations
  • Pharmaceutical industry
  • Transparency

ASJC Scopus subject areas

  • Health Policy

Cite this

Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK. / Rickard, Emily; Ozieranski, Piotr; Mulinari, Shai.

In: Health Policy, Vol. 123, No. 12, 01.12.2019, p. 1244-1250.

Research output: Contribution to journalArticle

@article{ca4b3df42e814eeb8d84fd5309764b8b,
title = "Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK",
abstract = "Patient organisations contribute to many areas of pharmaceutical policy. In developing their organisational capacity, many turn to financial support from pharmaceutical companies, which may create conflicts of interests. However, the transparency of the industry's self-regulatory approach to the disclosure of payments to patient organisations has evaded scrutiny. Using company reports disclosing payments to UK patient organisations in 2012–2016, we evaluate the transparency of reporting using indicators derived from industry's European patient organisation Code. We found a large proportion of companies did not have any disclosure reports available despite many having made payments, confirmed by comparing with annual financial accounts of patient organisations registered as charities. Where disclosure reports were available, many payments were not adequately described, resulting in large portions of money being disclosed without clarity as to the payment type and purpose. We found companies were clearer regarding whether payments were financial or benefits-in-kind, but transparency was particularly inadequate as to whether it could be determined if payments were indirect or direct and restricted or unrestricted, and almost no companies mentioned the VAT status of payments. Our findings suggest that the industry's self-regulatory approach to transparency has not been working efficiently. We suggest ways for standardising and increasing the precision of information by pharmaceutical companies and advocate for the introduction of a centralised, and easily accessible national-level payment database.",
keywords = "Disclosure, Patient organisations, Pharmaceutical industry, Transparency",
author = "Emily Rickard and Piotr Ozieranski and Shai Mulinari",
year = "2019",
month = "12",
day = "1",
doi = "10.1016/j.healthpol.2019.08.007",
language = "English",
volume = "123",
pages = "1244--1250",
journal = "Health Policy",
issn = "0168-8510",
publisher = "Elsevier Ireland Ltd",
number = "12",

}

TY - JOUR

T1 - Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK

AU - Rickard, Emily

AU - Ozieranski, Piotr

AU - Mulinari, Shai

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Patient organisations contribute to many areas of pharmaceutical policy. In developing their organisational capacity, many turn to financial support from pharmaceutical companies, which may create conflicts of interests. However, the transparency of the industry's self-regulatory approach to the disclosure of payments to patient organisations has evaded scrutiny. Using company reports disclosing payments to UK patient organisations in 2012–2016, we evaluate the transparency of reporting using indicators derived from industry's European patient organisation Code. We found a large proportion of companies did not have any disclosure reports available despite many having made payments, confirmed by comparing with annual financial accounts of patient organisations registered as charities. Where disclosure reports were available, many payments were not adequately described, resulting in large portions of money being disclosed without clarity as to the payment type and purpose. We found companies were clearer regarding whether payments were financial or benefits-in-kind, but transparency was particularly inadequate as to whether it could be determined if payments were indirect or direct and restricted or unrestricted, and almost no companies mentioned the VAT status of payments. Our findings suggest that the industry's self-regulatory approach to transparency has not been working efficiently. We suggest ways for standardising and increasing the precision of information by pharmaceutical companies and advocate for the introduction of a centralised, and easily accessible national-level payment database.

AB - Patient organisations contribute to many areas of pharmaceutical policy. In developing their organisational capacity, many turn to financial support from pharmaceutical companies, which may create conflicts of interests. However, the transparency of the industry's self-regulatory approach to the disclosure of payments to patient organisations has evaded scrutiny. Using company reports disclosing payments to UK patient organisations in 2012–2016, we evaluate the transparency of reporting using indicators derived from industry's European patient organisation Code. We found a large proportion of companies did not have any disclosure reports available despite many having made payments, confirmed by comparing with annual financial accounts of patient organisations registered as charities. Where disclosure reports were available, many payments were not adequately described, resulting in large portions of money being disclosed without clarity as to the payment type and purpose. We found companies were clearer regarding whether payments were financial or benefits-in-kind, but transparency was particularly inadequate as to whether it could be determined if payments were indirect or direct and restricted or unrestricted, and almost no companies mentioned the VAT status of payments. Our findings suggest that the industry's self-regulatory approach to transparency has not been working efficiently. We suggest ways for standardising and increasing the precision of information by pharmaceutical companies and advocate for the introduction of a centralised, and easily accessible national-level payment database.

KW - Disclosure

KW - Patient organisations

KW - Pharmaceutical industry

KW - Transparency

UR - http://www.scopus.com/inward/record.url?scp=85071089681&partnerID=8YFLogxK

U2 - 10.1016/j.healthpol.2019.08.007

DO - 10.1016/j.healthpol.2019.08.007

M3 - Article

AN - SCOPUS:85071089681

VL - 123

SP - 1244

EP - 1250

JO - Health Policy

JF - Health Policy

SN - 0168-8510

IS - 12

ER -